Sonus names new president
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the company and will add chairman to his title. Martino comes to Sonus from the nuclear medicine division of Mallinckrodt of St. Louis, which has a product marketing alliance with Sonus rival Molecular Biosystems.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
